UCB’s FINTEPLA (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.\n\n\n\nThe approval by the European Commission (EC) was based on safety and efficacy data from a global, randomized, placebo-controlled phase 3 clinical trial, in 263 patients with LGS (aged 2-35 years), which demonstrated adjunctive fenfluramine at a dose of 0.7/mg/kg/day provided a significantly greater reduction in the frequency of drop seizures compared to placebo. The most common treatment-emergent adverse events were decreased appetite, somnolence, fatigue, and pyrexia (fever). No cases of valvular heart disease or pulmonary arterial hypertension were observed.\n\n\n\nRima Nabbout, professor of pediatric neurology at University Paris cité, APHP, Necker Enfants Malades, Institut Imagine, Paris, France, said: “LGS is a developmental and epileptic encephalopathy where seizures are frequent, inducing high level of trauma injuries and negatively impacting development and quality of life. Seizures are often resistant to currently available medications, making this approval especially important for the individuals affected and their families.”\n\n\n\nUCB’s FINTEPLA: a new important treatment option\n\n\n\nMike Davis, head of global epilepsy and rare syndromes, UCB, said: “With this approval, fenfluramine is now an important additional treatment option for those impacted by this difficult to treat condition in Europe. This approval underscores our commitment to improving treatment outcomes, while addressing the high unmet need for new treatments for people living with LGS and rare epilepsies.”\n\n\n\nLennox-Gastaut syndrome\n\n\n\nLGS is a severe childhood-onset developmental and epileptic encephalopathy (DEE) characterized by multiple types of drug-resistant seizures with high morbidity, as well as serious impairment of neurodevelopmental, cognitive, and motor functions, affecting an estimated 2 in 10,000 people in the European Union (EU).\n\n\n\nSeizures leading to falls (drop attacks/seizures) are common in LGS and tonic seizures are a hallmark feature of this syndrome.\n\n\n\nIn addition, convulsive seizures (e.g., generalized tonic-clonic [GTC] seizures) are also commonly observed and usually occur in later stages of LGS, but sometimes may precede core seizure types. In addition to being associated with injury and hospitalizations, GTC seizures are a primary risk factor of sudden unexpected death in epilepsy (SUDEP). Patients with GTC seizures have an approximately 10-fold greater risk for SUDEP than patients with other seizure types.\n\n\n\nAdditionally, the EC has also adopted the EMA Committee for Orphan Medicinal Products (COMP) recommendation that the orphan designation for fenfluramine be maintained.